Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Nebivolol

Nebivolol

Cardioselective Ξ²1 blocker (NO-modulating)

AdultBBHTN

Indication

HTN β€’ AF rate adjunct β€’ chronic CAD context

At a glance

INDICATIONS (CORE USE)

**HTN** with Ξ²1-selective profile; still airway caution.

ADULT DOSE (STANDARD)

**PO:** **2.5–5 mg daily** start β†’ titrate to **BP/HR** per label (some patients **10 mg**)

MAX DOSE

**10 mg daily** typical HTN max β€” verify label / hepatic status

Route

PO (single formulation); not interchangeable mg-for-mg with other beta-blockers

PEDIATRIC DOSE

Not standard

Do not miss

Must-not-miss safety points

Major warning

- Bradycardia - HF decompensation β€” hold new start - Hepatic impairment dosing

Indications

USE IF: HTN and selected rate-control contexts. AVOID IF: severe bradycardia, acute decompensated HF, or severe hepatic failure per label.

Primary

  • Hypertension

Secondary

  • Atrial fibrillation β€” **rate control** (adjunct)
  • Chronic CAD context

Dosing

STANDARD (ADULT PO)

**Once daily**

ADULT DOSE

Start **2.5–5 mg QD** β†’ increase to **10 mg** if needed and tolerated.

PEDIATRIC DOSE

N/A

MAX DOSE

**10 mg/day** common ceiling β€” **hepatic** impairment may require lower max

Practical Note

**CYP2D6** poor metabolizers β€” higher exposure; START low and monitor BP/HR.

Warnings

Clinical warnings

  • Beta1-selective β€” caution in asthma / bronchospasm; not asthma-proof at higher doses. HOLD if HR <50–55, SBP <90–100, symptomatic bradycardia, high-grade AV block, or acute decompensated HF with shock/hypoperfusion.
  • Asthma β€” caution (not asthma-proof)
  • CYP2D6 phenotype variability

Adverse effects

  • Headache
  • fatigue
  • bradycardia
  • dizziness

Contraindications

  • Severe bradycardia
  • Cardiogenic shock
  • High-grade AV block (without pacing)

Drug interactions

  • Verapamil / diltiazem: avoid or use extreme caution (bradycardia / AV block / hypotension / shock risk)
  • Digoxin: additive AV-node suppression / AV block risk
  • Insulin / sulfonylureas: masks hypoglycemia warning
  • CYP2D6 inhibitors: increased exposure

Special populations

Pediatrics

Not standard

Pregnancy

**Pregnancy:** insufficient data β€” prefer **labetalol** for HTN if available. **

Lactation

** unknown β€” caution.

Renal impairment

Severe renal impairment β€” per label dose limits.

Hepatic impairment

**Moderate hepatic impairment** β€” start **2.5 mg**; **severe** often avoid.

Elderly

Conservative start β€” orthostasis.

Administration

PO with or without food per label.

Monitoring

  • Monitor: - Symptoms β†’ dizziness, syncope, fatigue
  • Recheck: - Reassess ECG / PR interval / AV block risk with symptoms, IV use, or dose escalation - Reassess dose / volume / cause within 48–72h after change - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - Hold if:
    - HR <50–55
    - SBP <90–100
    - Symptomatic bradycardia
    - Acute decompensated HF
    - Hypoperfusion / cardiogenic shock
    - Pulmonary edema requiring IV therapy

    Also hold:
    - High-grade AV block
    - Severe orthostasis

Overdose / toxicity

Clinical Picture

A) Mild β†’ bradycardia, hypotension, fatigue B) Moderate β†’ sustained bradycardia + hypotension Β± AV block C) Severe β†’ shock, high-grade AV block, seizures / coma (severe toxicity)

Immediate Actions

β€’ Airway + continuous monitoring first (ABCs, telemetry, BP) β€’ Bradycardia β†’ atropine β€’ Hypotension β†’ IV fluids β€’ Early β†’ IV calcium (CaCl2 / Ca-gluconate) β€’ Glucagon 3–5 mg IV β€’ Repeat or escalate glucagon β†’ infusion if responsive (often transient) β€’ Persistent shock β†’ HIET (insulin + dextrose) β€’ Monitor glucose + potassium closely β€’ Add vasopressors if shock persists β€’ Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) β€’ Refractory severe lipophilic toxicity β†’ IV lipid emulsion (toxicology-guided) β€’ Pacing β†’ symptomatic high-grade AV block β€’ ECMO β†’ refractory shock (per center) β€’ Severe / unstable β†’ ACLS + ICU / toxicology

Antidote

- Glucagon β†’ non-Ξ² pathway (often transient) - IV calcium β†’ inotropy / conduction support - HIET β†’ metabolic rescue (refractory shock) - IV lipid β†’ lipophilic toxicity (refractory / seizures)

Decontamination

β€’ Recent **oral** ingestion β†’ **activated charcoal** if **protected airway** and within **~1–2 h** (ingestion history + risk/benefit)

Escalation

- Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) - Pacing β†’ symptomatic high-grade AV block - ECMO β†’ refractory shock (per center)

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

NO-mediated vasodilation may reduce peripheral vasoconstrictive feel versus some traditional beta-blockers.

Clinical pearls

Not interchangeable mg-for-mg with **metoprolol**. *Ξ²-blockers (class):* **Start low, go slow.** **HF:** only **evidence-based agents** (**metoprolol succinate**, **bisoprolol**, **carvedilol**) for **HFrEF GDMT** β€” not all Ξ²-blockers interchangeable. **Rate control (AF)** vs **BP lowering** β€” titrate to the clinical target.

Beta-blocker safety

  • Check hepatic function
  • BP sitting and standing early

Pharmacokinetics

Hepatic metabolism β€” **active metabolites**; **CYP2D6** affects levels.

Mechanism of action

**Highly selective Ξ²1** antagonism + **NO-related vasodilation** (contributes to BP effect).

Common brand names

Saudi Arabia

Nebilet, Bystolic

Global

(placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Acute **aortic syndromes** and **thyrotoxic storm** are **protocol-driven** β€” Ξ²-blocker choice and targets are **team + guideline** specific.
  • Ξ²-blocker **GDMT for HFrEF** applies only to **evidence-based agents** β€” verify label and cardiology plan before substituting.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)

Do not miss

  • Teach **not to stop abruptly** after chronic use β€” taper when feasible
  • Titrate to **HR vs BP endpoint** (AF rate control often needs higher exposure than BP alone)
  • Check hepatic function
  • BP sitting and standing early